We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more
Regulatory News: Carmila (Paris:CARM) announces completion of the acquisition of 7% of the share capital of Galimmo SCA for a total consideration of 27 million euros, or 11.93 euros per share. On...
Regulatory News: Carmila (Paris:CARM) a confié à un prestataire de service d’investissement un mandat de rachat d’actions portant sur un montant maximum de 10 millions d’euros. La période d’achat...
Regulatory News : Carmila (Paris:CARM) annonce avoir mis à disposition du public et déposé le 24 juillet 2024 son rapport financier semestriel 2024 auprès de l’Autorité des marchés financiers. Il...
Regulatory News: Carmila (Paris:CARM) has made available to the public and filed with the French financial markets authority (Autorité des Marchés Financiers) its 2024 Half Year Financial Report...
Regulatory News: Carmila (Paris:CARM): Key information Recurring earnings per share of €0.87, up by 2.4% versus first-half 2023 Guidance revised upwards: recurring earnings per share of €1.65 now...
Regulatory News: At 30 June 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CA) with Kepler Cheuvreux were the following: - 80,485 CARMILA shares; - Euro...
Regulatory News: CARMILA (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto- détenues) Nombre théorique de droits de...
Carmila announces the closing of the acquisition of 93% of the share capital of Galimmo SCA Galimmo’s portfolio of 52 assets, mainly located in the North-East of France, was valued at 675...
Carmila annonce la finalisation de l’acquisition de 93% du capital de Galimmo SCA Les 52 actifs de Galimmo, situés principalement dans le nord-est de la France, sont valorisés à 675 millions...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -3.36134453782 | 1.19 | 1.19 | 1.03 | 217873 | 1.102013 | CS |
| 4 | -0.49 | -29.8780487805 | 1.64 | 1.9 | 1.03 | 1934396 | 1.47222295 | CS |
| 12 | -0.49 | -29.8780487805 | 1.64 | 1.9 | 0.99 | 854294 | 1.42493993 | CS |
| 26 | -1.1 | -48.8888888889 | 2.25 | 2.77 | 0.99 | 477722 | 1.56144011 | CS |
| 52 | -5.46 | -82.602118003 | 6.61 | 7.144 | 0.99 | 338736 | 2.25004311 | CS |
| 156 | -4.64 | -80.1381692573 | 5.79 | 9.7662 | 0.99 | 321743 | 3.23321743 | CS |
| 260 | -4.64 | -80.1381692573 | 5.79 | 9.7662 | 0.99 | 321743 | 3.23321743 | CS |
PonkenPlonken
4 weeks ago
glenn1919
4 weeks ago
Awl416
4 weeks ago
Termite7
2 months ago
axelvento
2 months ago
PonkenPlonken
3 months ago
Monksdream
4 months ago
mrplmer
7 months ago
mrplmer
7 months ago
81vette
7 months ago
81vette
7 months ago
stock1ace1
7 months ago
81vette
7 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
